New appointment at NormOxys
This article was originally published in Scrip
Executive Summary
NormOxys, a US-based biotechnology company developing a class of small-molecule drugs which enhance the body’s ability to deliver oxygen to diseased tissues, has appointed Dr John Hey senior vice-president of preclinical and early development. In the role, he will be responsible for the drug discovery and preclinical drug development activities for the company's platform of novel oxyren compounds, as well as all preclinical research. Dr Hey, who has than 20 years' drug discovery and development experience, joins from CoMentis, where he served as senior vice-president of discovery and preclinical drug development.
You may also be interested in...
Morgan Lewis expands FDA & healthcare practice
US-based law firm Morgan Lewis has appointed Donna Lee Yesner and Stephen Ruscus as partners in its Food and Drug Administration and healthcare practice, based in Washington, DC. Ms Yesner is the co-chair of the healthcare contracting committee of the ABA Public Contracts Section, while Mr Ruscus focuses his practice on public healthcare, government contracts and litigation.
Qforma appoints new member to board
Qforma, a provider of analytics and predictive modelling technologies for the health sciences industry, has elected Mark Spiers to its board of directors. Mr Spiers retired as president and CEO of Wolters Kluwer Pharma Solutions in April; he has also previously worked for Bristol-Myers Squibb, Pharmacia and MedPointe Pharmaceuticals.
Optimer expands management team
The San Diego, California-based biopharmaceutical company Optimer Pharmaceuticals has appointed Dr Nancy Ruiz senior vice-president of R&D, Cynthia Schwalm senior vice-president of international and Dr Kasia Petchel senior vice-president of pharmacovigilance. These newly created positions will strengthen the company's management team as it prepares for the potential launch of its lead product candidate, Dificid (fidaxomicin). Dr Ruiz joins from Merck Research Laboratories (formerly Schering-Plough Research Institute), where she served as vice-president of project and pipeline management for infectious diseases. Ms. Schwalm was previously president of Eisai Pharmaceuticals, the US commercial arm of Tokyo-based Eisai Co, while Dr Petchel was formerly vice-president of global head drug safety risk management at Roche.